[1] Ding S, Guo LX.Mechanism of sodium-glucose cotransporter and related drugs[J]. Chin J Diabetes Mellitus(中华糖尿病杂志), 2016, 8(5):319-320. [2] Medscape. DAPA HF: Dapagliflozin Offers New HF Therapy, Even Sans Diabetes.[EB/OL].(2019-09-01)[2019-09-15] http://news. medlive.cn/heart/info-progress/show-161353_129.html. [3] Zinman B, Wanner C, Lachin JM, et al.Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128. [4] Kitabchi AE, Umpierrez GE, Miles JM, et al.Hyperglycemic crises in adult patients with diabetes[J]. Diabetes Care, 2009,32(7):1335-1343. [5] Chou YM, Seak CJ, Goh ZNL,et al, Lin CC. Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report[J]. Medicine (Baltimore),2018, 97(25):e11056. [6] Levine JA, Karam SL, Aleppo G.SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns[J]. Current Diabetes Reports,2017, 17(7):54. [7] Ogawa W, Sakaguchi K.Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors[J]. J Diabetes Invest, 2016(7):135-138. [8] Lane S, Paskar D, Hamed S, et al.When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report[J]. A A Pract,2018,11(2):46-48. [9] Peters AL, Buschur EO, Buse JB, et al.Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition[J]. Diabetes Care, 2015,38(9):1687-1693. [10] Burke KR, Schumacher CA, Harpe SE.SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature[J]. Pharmacotherapy, 2017,37(2):187-194. [11] Lin YH.Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors[J]. J Formos Med Assoc, 2018,117(9):849-854. [12] Balasubramanyam A, Zern JW, Hyman DJ, et al.New profiles of diabetic ketoacidosis: type 1 vs type 2 diabetes and the effect of ethnicity[J]. Arch Intern Med, 1999,159(19):2317-2322. [13] Jazi M, Porfiris G.Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor[J]. Can Fam Physician, 2016, 62(9):722-724. [14] Taylor SI, Blau JE, Rother KI.SGLT2 Inhibitors May Predispose to Ketoacidosis[J]. J Clin Endocrinol Metab, 2015,100(8):2849-2852. [15] Gil-Perdomo JM, Fari a GTF, Jordán-Arias B, et al. Diabetic ketoacidosis inducing myocardial infarction secondary to treatment with dapagliflozin: a case report[J]. Clin Case Rep, 2017,5(6):809-811. [16] Chinese Society of Endocrinology. Chinese consensus guidelines for monitoring diabetes blood ketones[J]. Chin J Endocrinol Metab(中华内分泌代谢杂志), 2014, 30(3): 177-183. [17] Zhang L, Tamilia M.Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor[J]. CMAJ, 2018,190(25):766-768. [18] Gajjar K, Luthra P.Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature[J]. Cureus, 2019,11(4):e4384. [19] Isaacs M, Tonks KT, Greenfield JR.Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors[J]. Intern Med J. 2017, 47(6):701-704. |